Related Experiment Video

Updated: Sep 25, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.0K

The Roles of KIFC1 in the Development of Osteosarcoma: Characterization of Potential Therapeutic Targets

Li-Yan Liang1, Gui-Shi Li2

  • 1Department of Intense Care Unit, Yantai Yuhuangding Hospital, No. 20 Yudong Road, Zhifu District, Yantai City, 264000 Shandong Province, China.

Computational and Mathematical Methods in Medicine
|April 28, 2022
PubMed
Abstract

Insights

Kinesin family member C1 (KIFC1) is upregulated in osteosarcoma (OS) and promotes tumor progression by increasing cell proliferation. This suggests KIFC1 is a potential therapeutic target for osteosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Kinesin family member C1 (KIFC1) is implicated in various cancers.
  • The role of KIFC1 in osteosarcoma (OS) development remains unclear.

Purpose of the Study:

  • To investigate the expression and function of KIFC1 in osteosarcoma.
  • To determine if KIFC1 could serve as a potential therapeutic target for OS.

Main Methods:

  • KIFC1 expression was analyzed in OS tissues using immunohistochemistry (IHC) and the GEPIA2 database.
  • KIFC1's correlation with CDC20 and patient prognosis was assessed.
  • KIFC1 was knocked down using short hairpin RNA (shRNA) in OS cell lines (MG-63, U-2 OS).
  • Cell proliferation and apoptosis were evaluated using CCK-8, colony formation, and apoptosis assays.

Main Results:

  • KIFC1 expression was significantly elevated in OS tissues compared to normal tissues and inversely correlated with patient prognosis.
  • KIFC1 expression was positively correlated with CDC20.
  • KIFC1 knockdown effectively reduced KIFC1 expression and inhibited cell proliferation while increasing apoptosis in OS cells.

Conclusions:

  • KIFC1 is upregulated in osteosarcoma and promotes tumor progression through enhanced cell proliferation.
  • KIFC1 represents a potential diagnostic and prognostic biomarker for OS.
  • KIFC1 inhibition may offer a novel therapeutic strategy for osteosarcoma treatment.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.3K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K